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Abstract
Amicoumacin A exhibits strong antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA), hence we
sought to uncover its mechanism of action. Genome-wide transcriptome analysis of S. aureus COL in response to
amicoumacin A showed alteration in transcription of genes specifying several cellular processes including cell envelope
turnover, cross-membrane transport, virulence, metabolism, and general stress response. The most highly induced gene
was lrgA, encoding an antiholin-like product, which is induced in cells undergoing a collapse of Dy. Consistent with the
notion that LrgA modulates murein hydrolase activity, COL grown in the presence of amicoumacin A showed reduced
autolysis, which was primarily caused by lower hydrolase activity. To gain further insight into the mechanism of action of
amicoumacin A, a whole genome comparison of wild-type COL and amicoumacin A-resistant mutants isolated by a serial
passage method was carried out. Single point mutations generating codon substitutions were uncovered in ksgA (encoding
RNA dimethyltransferase), fusA (elongation factor G), dnaG (primase), lacD (tagatose 1,6-bisphosphate aldolase), and
SACOL0611 (a putative glycosyl transferase). The codon substitutions in EF-G that cause amicoumacin A resistance and
fusidic acid resistance reside in separate domains and do not bring about cross resistance. Taken together, these results
suggest that amicoumacin A might cause perturbation of the cell membrane and lead to energy dissipation. Decreased
rates of cellular metabolism including protein synthesis and DNA replication in resistant strains might allow cells to
compensate for membrane dysfunction and thus increase cell survivability.
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Introduction
Staphylococcus aureus is the etiological agent for a large number of
human infections, including pneumonia, meningitis, toxic shock
syndrome, bacteremia, and endocarditis. S. aureus is notorious for
developing rapid resistance to antibiotics, which is caused mainly
by antibiotic selection and horizontal transfer of resistance genes
[1]. Most notably, methicillin-resistant S. aureus (MRSA) has
emerged quickly due to acquisition of the novel penicillin-binding
protein 2A (PBP2A) encoded by mecA [2]. The mecA gene likely
originated from Staphylococcus sciuri that is naturally sensitive to b-
lactam [3] and mecA incorporated into a staphylococcal cassette
chromosome (SCCmec) serves as a mobile genetic element, thus
mediating transfer of the mecA gene into staphylococcal species [4].
Morbidity caused by MRSA infections per year in the U.S.A. was
reported to be comparable to that caused by HIV/AIDS [5],
which highlights the importance of this deadly pathogen. The
glycopeptide vancomycin, the most commonly used antibiotic for
the treatment of MRSA infections, is no longer effective enough
because of the emergence of vancomycin-intermediate S. aureus
(VISA) [6]. Therefore, there is an urgent need to find antibacterial
agents with novel mechanisms of action and to understand how S.
aureus acquires antibiotic resistance.
In this study, amicoumacin A, which possesses strong anti-
MRSA activity, was investigated. Amicoumacin A, also known as
AI-77-A, is one of numerous structurally related isocoumarin
antibiotics [7,8,9,10]. Other examples of this class of antibiotics
include the xenocoumacins, the bacilosarcins, Sg17-1-4, PM-
94128, and Y-05460 [11,12,13,14,15]. Figure 1 illustrates the
structures of amicoumacin A and xenocoumacin 1. These
isocoumarins exhibit a wide variety of biological effects, ranging
from anti-bacterial to anti-tumor activity [11,12,13,14,15].
Amicoumacin A has anti-microbial, anti-inflammatory, and anti-
ulcer properties [7], and anti-Helicobacter activity was later reported
[16]. Despite the versatile activities, the mode of action remains
unknown. Antibiotics currently used for MRSA infections either
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membrane (daptomycin) [18]. Amicoumacin A was reported to
exhibit anti-MRSA activity [19]. This work has been aimed at
elucidating the mechanism of action of amicoumacin A by
examining genome-wide transcription induced by exposure of
MRSA to amicoumacin A and identifying genetic changes that
lead to reduced susceptibility to amicoumacin A.
Results
Isolation and identification of Bacillus pumilus strain C9
with anti-MRSA activity
A collection of 60 bacterial strains isolated from the Columbia
River Estuary was screened for their potential antimicrobial
activity against S. aureus. Three isolates exhibited clear inhibitory
zones and were identified as Pseudoalteromonas tunicata, Peudoalter-
omonas sp., and B. pumilus based on the analysis of 16S rRNA gene
sequence. Among the three strains, B. pumilus (named the strain
C9) had the strongest activity against methicillin-sensitive S. aureus
(MSSA) and MRSA and was chosen for further investigation.
Purification and characterization of amicoumacin A
To identify its structure, the anti-MRSA substance was purified
by methanol extraction, anion exchange column chromatography
and RP-HPLC. The molecular mass of the compound was
determined to be 424.2077 Da as determined by nanoESI FTICR
mass spectrometry. FTICR analysis also revealed a plausible
chemical formula (C20H30N3O7) for the substance. Through
NMR analysis of the compound, chemical shifts and coupling
constants were assigned for the protons in the molecule.
Comparisons of the molecular mass, molecular formula and
NMR data with the literature suggested that this substance is
identical to amicoumacin A [7] (Figure 1).
Seven B. pumilus strains obtained from the Bacillus Genetic Stock
Center were also checked for their anti-MRSA activity. No activity
was detected from these strains except that 8A2 showed a weak
anti-MRSA activity. However, the antibacterial spectrum of the
compound from 8A2 significantly differed from that of the
substance from C9 (data not shown). On the other hand, a similar
anti-MRSA activity was detected in B. pumilus SAFR-032, a strain
originally recovered from the Jet Propulsion Lab (Pasadena, CA)
spacecraft assembly facility [20]. The results suggested that
productivity of amicoumacin A was lost during domestication of
B. pumilus strains and in fact, we have previously found a similar
phenomenon for surfactin production in B. subtilis 168. In this
case, introduction of sfp into domesticated B. subtilis strains
restored surfactin production [21]. The sfp gene encodes 49-
phosphopantetheine transferase essential for nonribosomal pep-
tides (NRP) and polyketides (PK) synthesis [22]. A recent study
showed that PK and NRP synthesis genes are required for the
production of xenocoumacin I [23], indicating that amicoumacin
A is likely synthesized by a PK/NRP complex. It is conceivable
that B. pumilus domesticated strains contain inactive sfp and hence
are incapable of producing amicoumacin A. We designed primers
using the sfp sequence of B. pumilus SAFR032 strain and used the
primers to detect a PCR product with chromosomal DNA isolated
from C9, 8A3, and 14A1. The PCR product with a high sequence
homology to sfp from SAFR032 was detected in C9, but not in
8A3 and 14A1 (unpublished results), which is consistent with the
notion that amicoumacin A is likely synthesized by a similar
mechanism and the lack of an intact sfp is partially (if not solely)
responsible for the loss of amicoumacin A production in
domesticated B. pumilus strains.
Antimicrobial spectrum of amicoumacin A
In order to evaluate the antimicrobial effect of amicoumacin A,
we examined the spectrum of amicoumacin A. Two gram-negative
bacteria, E. coli and Pseudomonas aeruginosa were resistant as were
three gram-positive bacteria, B. pumilus, Bacillus subtilis, and Listeria
monocytogenes. Among the susceptible gram-positive bacteria,
Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis showed a
moderate sensitivity. These bacteria exhibited a fairly large zone of
inhibition (,2 cm in diameter) after 4–5 h of incubation with
amicoumacin A; however, several resistant colonies appeared after
overnight incubation and the inhibition zone became smaller
(0.5 cm in diameter). In contrast, amicoumacin A showed highly
potent activity (inhibition zone .2 cm in diameter after overnight
incubation) against all MSSA and MRSA strains tested including
hospital-acquired MRSA (HA-MRSA), community-acquired
MRSA (CA-MRSA), and Mu50, a HA-MRSA/VISA strain. In
addition, Staphylococcus carnosus and Streptococcus pyogenes are sensitive
to amicoumacin A at a level similar to S. aureus strains. These
results indicated that amicoumacin A is highly effective against
gram-positive cocci including important pathogens.
Effect of amicoumacin A on the growth of S. aureus COL
The effect of amicoumacin A on the growth and survival of S.
aureus COL was examined. As shown in Figure 2, the growth was
inhibited after treatment with amicoumacin A and there was a
significant ,3-log10 decrease in the number of viable S. aureus cells.
These effects on the growth and survival are similar to those by a
bactericidal antibiotic vancomycin (Fig. 2), indicating that
amicoumacin A is a bactericidal antibiotic as reported in H. pylori
[16].
Changes in global transcription of S. aureus COL in
response to amicoumacin A
Transcriptome analysis has been used to identify changes in
gene expression in response to antibiotic treatment (reviewed in
[24]). Samples were taken at 0, 10, and 40 min (t0,t 10, and t40,
respectively) after COL was treated with amicoumacin A and
RNA was purified as described in Materials and Methods.
Microarray experiments were carried out on three independent
Figure 1. The chemical structures of amicoumacin A and
xenocoumacin 1.
doi:10.1371/journal.pone.0034037.g001
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information (Table S1, all genes with a minimum 2.5-fold up or
down change) and Table 1 shows a list of selected genes that are
upregulated more than 3-fold at 10 min after the treatment
compared to unexposed control cells.
In total, we identified 263 upregulated and 282 downregulated
genes.
The overall transcriptome results indicated that genes involved
in diverse biological processes are upregulated, which is similar to
the transcriptome in response to unsaturated long chain free fatty
acids [25]. Particularly intriguing is that 46 genes were co-
upregulated and 27 co-downregulated by amicoumacin A and
linoleic acid. Of the 46 co-upregulated genes, 30 belong to the S.
aureus s
B-regulon [26,27]. s
B is an alternative s factor functioning
in general stress response, the mechanism of which has been
extensively studied in B. subtilis (reviewed in [28,29]). A previous
study suggested that s
B of S. aureus functions in more basic cell
physiology compared to the B. subtilis counterpart [27]. The s
B-
controlled genes upregulated by amicoumacin A were either
transiently upregulated at t10 only or were upregulated at t10 and
t40. We examined whether the sigB mutation leads to a higher
susceptibility to amicoumacin A; however, the growth curve assay
did not show any significant effect of the sigB mutation on
amicoumacin A susceptibility (data not shown).
An annotation-based grouping of amicoumacin A regulated
genes highlighted a particularly high number of induced genes
with cell envelope and transport related processes. In total, 21
genes with cell envelope associated functions were upregulated
including lrgA (SACOL0247) and lrgB (SACOL0248), which are
among the most highly induced genes (Table 1). The lrgA gene and
its homologous gene cidA are known to regulate murein hydrolase
activity and affect sensitivity to penicillin [30,31]. CidA is a holin-
like protein that positively controls murein hydrolase activity and
penicillin-induced killing, which is antagonized by LrgA, an anti-
holin [30,31]. Consistent with the notion, cidA transcription is
regulated oppositely from lrgAB in response to amicoumacin A.
The microarray result showed that cidA is downregulated 1.9-fold
at 10 min, whereas expression of the downstream cidB and cidC
gene is upregulated 2.8-fold and 4.2-fold, respectively, which was
confirmed by Northern blot analysis (data not shown).
In addition, transcription of three peptidoglycan hydrolases (atl,
lytM and sceD) was strongly upregulated in amicoumacin-A-treated
cells. Transcription of atl encoding the major autolysin of S. aureus
was about 4-fold induced at t10 and t40, while sceD encoding a lytic
transglycosylase [32] was 2-fold induced at t10 and over 10-fold at
t40. Similar to sceD, transcription of lytM, a Gly-Gly endopeptidase
[33], was 4-fold induced at t40. Another group of upregulated
genes encode proteins that function in cell wall and surface
polysaccharides synthesis and turnover, which include a penicillin-
binding protein (SACOL1490), MurG (SACOL1453), a predicted
glycosyl-transferase (SACOL2578), and N-acetylmuramoyl-L-ala-
nine amidase (SACOL1825) [34]. In addition, over 46 genes
encoding proteins with functions in membrane transport were
upregulated.
Validation of microarray results
Northern blot analysis was carried out with two independently
isolated RNA samples to validate the microarray results. Five
operons and one gene were randomly chosen and the results of
two operons are shown in Figure 3. The operon of eight genes
(SACOL0678 to SACOL0686) encodes a phage integrase family
protein (SACOL0678) and monovalent cation/H
+ antiporter
subunits (SACOL0679 to 0686). A previous study showed that
Figure 2. Effect of amicoumacin A (A and B) and vancomycin (C and D) on S. aureus COL. (A) COL was grown in TSB and exponential
growth phase cultures were divided into two flasks. Amicoumacin-A-treated (closed circles) and -untreated cultures (open circles) were further
incubated and the optical density at 600 nm was measured at hourly intervals. Effect of inhibitory levels of amicoumacin A during longer cultivation
is shown in the insert of Figure 2A. (B) The cultures in (A) were used to examine viable cell counts by plating diluted cells on TSB agar. (C) COL was
treated with 10 mg/ml of vancomycin and growth was monitored as described in (A). (D) The cultures in (C) were used to examine viable cell counts.
The data are the average of three independent experiments with standard deviations.
doi:10.1371/journal.pone.0034037.g002
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B-dependent [27]. Based on the
microarray result, all eight genes were induced at t10 and the
increased level of transcription was sustained at similar levels at t40
(Table 1 and Table S1). In the Northern blot experiment, a low
level of 6.8 kb transcript was detected in untreated cells and the
transcript was highly elevated at t10 and t40 (Figure 3A). This result
confirmed that the eight genes constitute an operon and that
amicoumacin A upregulates the operon transcription as shown by
the microarray hybridization result. Transcription of another
operon starting from SACOL2176 was also upregulated at t10 in
the microarray results but the transcription decreased to the
untreated level at t40 (Table 1 and Table S1). SACOL2176
encodes an osmoprotectant transporter, SACOL2175 and SA-
COL2174 encode a protein of unknown function and a membrane
protein, respectively, and SACOL2173 is asp23 that codes for
alkaline shock protein 23 [35]. The Northern blot analysis
detected three transcripts of 3.0 kb, 1.5 kb, and 0.6 kb, all of
which increase at t10 but not at t40 (Figure 3B). The sizes of the
transcripts correspond to the predicted transcripts initiated at the
three s
B-dependent promoters. In a similar way, we also validated
the microarray result of SACOL0673-0672-0671, SACOL2596-
2597, SACOL02554.1-2554-2553, and SACOL1062 (data not
shown).
Effect of amicoumacin A on autolysis
The transcriptome results showed that lrgA transcription is
highly upregulated and cidA transcription is downregulated by
amicoumacin A. It has been shown that the cidA mutation reduces
murein hydrolase activity [31], whereas the lrgAB mutation
increases activity [30]. This result implied that autolysis might
be reduced in response to amicoumacin A. On the other hand, the
major autolysin gene atl was upregulated by amicoumacin A
treatment (Table 1), suggesting that amicoumacin A might cause
increased autolysis. To determine which possibility is correct, we
investigated whether and how amicoumacin A affects autolysis.
Figure 4A showed that amicoumacin-A-treated cells are more
resistant to Triton X-100-induced lysis than untreated cells.
Therefore, increased transcription of atl did not result in higher
autolysis, which is consistent with the model that LrgA/CidA
Table 1. Selected genes induced 3-fold or above by amicoumacin A.
COL ORF Fold induction Gene product
T10 T40
Cell envelope
SACOL0248
a 14.0 1.4 LrgB, antiholin
SACOL0247
a 8.6 1.0 LrgA, murein hydrolase regulator 2
SACOL2197 9.2 11.9 Surface protein + s
B
SACOL2557 4.3 2.7 N-acetylmuramoyl-L-alanine amidase
SACOL1062 3.9 4.0 Atl, bifunctional autolysin + s
B
SACOL0671
b 3.9 2.2 a/b-fold family hydrolase + s
B
SACOL2597 3.5 1.4 a/b-fold family hydrolase + s
B
SACOL2019 3.8 3.3 SdrH protein 2
SACOL2434 3.0 3.2 cell surface polysaccharide synthesis + s
B
Transporter
SACOL2138
c 6.7 7.8 Cation efflux family protein
SACOL2136
c 4.1 1.4 Hypothetical s
B
SACOL0264 4.0 4.5 ABC transporter
SACOL2176 3.8 2.2 OpuD2, osmoprotectant transporter + s
B
SACOL0681
d 3.3 3.5 monovalent cation/H
+ antiporter C s
B
SACOL0679
d 3.1 2.8 monovalent cation/H
+ antiporter A s
B
SACOL0682
d 3.0 3.1 monovalent cation/H
+ antiporter D s
B
SACOL0680
d 3.0 3.1 monovalent cation/H
+ antiporter B s
B
SACOL1422 3.1 3.7 phosphate ABC transporter
Virulence
SACOL2295 5.5 7.2 Staphyloxanthin biosynthesis
SACOL0136
e 3.8 2.7 Cap5A, capsular polysaccharide biosynthesis s
B
SACOL0137
e 3.0 2.3 Cap5B, capsular polysaccharide biosynthesis s
B
SACOL0138
e 3.4 2.0 Cap5C, capsular polysaccharide biosynthesis s
B
SACOL0672
b 3.4 2.0 SarA, staphylococcal accessory regulator +
SACOL0856 3.3 3.0 clumping factor + s
B
SACOL2511 3.0 5.4 fibronectin-binding protein
Superscript alphabet indicates genes in the same operon. + and 2 arrows show genes induced or repressed in response to linoleic acid based on [25]. s
B-controlled
genes are marked.
doi:10.1371/journal.pone.0034037.t001
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[36].
To distinguish whether the reduced autolysis is due to
alterations of cell wall or to decreased activity of autolysin,
purified cell wall and extracellular autolysin were prepared from
cells grown in the presence and absence of amicoumacin A.
Previous work showed that overexpression of lrgAB in S. aureus
leads to decreased extracellular murein hydrolase activity [30]. We
first conducted an experiment designed to determine if amicou-
macin A inhibits autolysis by reducing extracellular autolysin
activity. Purified cell wall from S. aureus COL was incubated with
an equal amount of extracellular proteins from untreated or
amicoumacin-A-treated cells (Figure 4B). No significant decrease
in OD600 was detected in the sample of purified cell wall alone,
confirming that it has no intrinsic autolysin activity. The addition
of extracellular proteins from untreated cells hydrolyzed over 50%
of cell wall after 7 h of incubation, whereas proteins from treated
cells did not hydrolyze purified cell wall, indicating that
amicoumacin A reduces murein hydrolase activity. In a reciprocal
experiment, we demonstrated that cell wall purified from strain
COL grown in the presence of amicoumacin A was susceptible to
extracellular autolysin from amicoumacin-A-untreated cells,
although the rate of hydrolysis was slightly slower than cell wall
prepared from untreated cells (Figure 4C). These results clearly
showed that reduced autolysis of S. aureus grown in the presence of
amicoumacin A is due to the lower level and/or activity of
autolysin.
We performed zymographic analysis to examine the autolysin
profile (Figure 4D). Both cell-wall-associated and extracellular
autolysin profiles were not significantly altered by amicoumacin A
treatment, but overall activities were reduced by the treatment.
Except for the 36 kDa protein identified as Aaa (autolysin/
adhesion protein of S. aureus) [37], the other six bands likely
represent differently processed forms of Atl [38,39]. Among these
Atl forms, the 113 kDa band, which corresponds to an
intermediate generated from pro-Atl by cleavage of the pro-
peptide, was particularly reduced in both cell wall and the
extracellular fraction of cells treated by amicoumacin A.
Isolation of mutants with decreased susceptibility
towards amicoumacin A
As amicoumacin A is highly effective against MRSA, we
investigated whether resistant mutants are associated with
antibiotic selection pressure. Identification of mutations that lead
to the amicoumacin A resistance might also provide clues to its
mechanism of action. We isolated strains with decreased
susceptibility to amicoumacin A using a serial passage of COL
in the presence of the compound. COL was able to grow in the
presence of successively higher concentrations of amicoumacin A
over time. The resistance increased 2-fold every two days.
Figure 3. Northern blot analyses for SACOL0678 (A) and SACOL2176 (B) operon. Total RNA was isolated from S. aureus COL at 0 (t0), 10
(t10), and 40 (t40) min after the addition of amicoumacin A. 10 mg of total RNA isolated from each culture was separated in a formaldehyde-agarose
gel and the RNA-blotted membrane was hybridized with SACOL0678- or SACOL2173(asp23)-specific digoxigenin-labeled probes. The sizes of the
transcripts were determined by comparison to an RNA ladder on the same gel. The corresponding stained gels are shown underneath each blot.
Schematic views of the gene loci based on NCBI COL genome site are shown with predicted transcripts. s
B indicates locations of s
B-controlled
promoters. Microarray results of each operon’s genes are summarized in the right panel of the corresponding Northern blot gels. Closed squares and
open squares show samples taken at t10 and t40, respectively. The average of triplicates and standard deviations are indicated.
doi:10.1371/journal.pone.0034037.g003
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resistance against amicoumacin A as compared to the wild-type
strain, further incubation up to 15 days did not increase resistance
(Figure 5).
Determination of the mutations associated with
increased resistance to amicoumacin A
Whole-genome sequencing becomes a powerful tool for
identifying genomic variation and was applied to track multidrug
resistance in S. aureus recovered periodically from a patient
undergoing chemotherapy with vancomycin [40]. We used the
approach to identify genetic changes present in the amicoumacin
A-resistant COL strains. Genome libraries were constructed from
three resistant strains, namely SA-1, SA-3, and SA-6 that exhibit
2-fold, 8-fold, and 16-fold increase in resistance, respectively. The
sequencing results uncovered a set of genes with varying numbers
of single nucleotide polymorphisms (SNPs) in the resistant mutants
(Table 2). The results revealed that more mutations were found in
parallel with increasing levels of resistance. Among the mutations,
SACOL0187 (in SA-1) and oppB (in SA-3) encode ABC-
transporters. Both SA-3 and SA-6 contain missense mutations in
fusA that encodes translation factor EF-G. Interestingly, the EF-G
amino acid substitutions occur at adjacent glycine residues. The
fusA gene has been known as the site of mutations that confer
fusidic acid resistance in Salmonella enterica serovar Typhimurium
[41] and S. aureus [42,43]. Fusidic acid is a steroid-like antibiotic
clinically used since the 1960s. Mutations that are responsible for
fusidic acid resistance occur in domains I, III, and V of EF-G, as
well as in domain II with less frequency, whereas the mutations
found in the amicoumacin A-resistant isolates reside in domain IV.
Figure 4. Effect of amicoumacin A on autolysis. (A) Effect on whole cell autolysis. Cultures grown in the absence (open circles) and the presence
(closed circles) of amicoumacin A were washed and suspended in autolysis buffer to an initial OD600 of around 1.0 and autolysis was monitored as
decline in OD600. (B) Quantitative assay of murein hydrolase activity against cell wall. An equal amount (90 mg protein) of extracellular proteins were
added to cell wall purified from amicoumacin-A-untreated cells and OD600 was monitored as described in Materials and Methods. Symbols: open
circles, extracellular proteins from untreated cells; closed circles, extracellular proteins from amicoumacin-A-treated cells; open triangles, 10 mM Tris-
HCl (pH 7.5). (C) Susceptibility assay of purified cell wall to murein hydrolase. Ninety mg of extracellular proteins from amicoumacin-A-untreated cells
were added to cell wall purified from amicoumacin-A-treated and -untreated cells and OD600 was monitored. Symbols: open circles, cell wall from
untreated cells with 10 mM Tris-HCl (pH 7.5); closed circles, cell wall from untreated cells with extracellular proteins; open triangles, cell wall from
amicoumacin-A-treated cells with 10 mM Tris-HCl (pH 7.5); closed triangles, cell wall from amicoumacin-A-treated cells with extracellular proteins. (D)
Zymographic analysis of murein hydrolase activity from amicoumacin-A-treated and -untreated cells against purified S. aureus COL cell wall. Autolytic
extracts were prepared and assayed by electrophoresis on an SDS-polyacrylamide gel (10%) containing 1 mg/ml purified cell wall as described in
Materials and Methods. Lanes: M, prestained molecular weight markers; 1, cell-wall-associated proteins from untreated cells; 2, cell-wall-associated
proteins from amicoumacin-A-treated cells; 3, extracellular proteins from untreated cells; 4, extracellular proteins from amicoumacin-A-treated cells.
doi:10.1371/journal.pone.0034037.g004
Figure 5. Serial passage experiments with S. aureus COL
selected for increasing resistance to amicoumacin A. Each circle
shows fold-resistance on each day.
doi:10.1371/journal.pone.0034037.g005
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identified point mutations. The ksgA gene encodes the methyl-
transferase for two adjacent adenosines in 16 S rRNA. Kasuga-
mycin resistance was shown to be associated with the loss of the
methylation [44]. Other mutations were identified in dnaG
encoding primase, lacD encoding tagatose 1,6-bisphosphate
aldolase, and SACOL0611, a putative glycosyl transferase gene.
Construction of the ksgA knockout mutation and
amicoumacin A resistance
To evaluate the role and impact of the ksgA mutation in
amicoumacin A resistance, the same mutation was re-created in
COL using plasmid pMAD with a temperature-sensitive replicon.
The mutant allele (L260stp) of the ksgA gene that lacks the start
codon was amplified by PCR and the product was cloned into
pMAD. The PCR product was designed to position the mutation
at the 39-end of the insert DNA, thus maximizing the chance of
homologous recombination at a region located the 59 to the site of
the mutation. A single crossover recombination of the resultant
plasmid into COL chromosomal DNA thus results in the mutant
ksgA gene expressed from the native promoter and inactivation of
the wild-type ksgA gene due to the loss of its promoter and deletion
of the 59-end of the gene. The integration of the plasmid in the
predicted manner was confirmed by PCR and sequence analysis of
the ksgA region of the resultant strain, SA-8. The MIC of
amicoumacin A increased 2-fold compared to the parent strain,
confirming that the nonsense ksgA allele is responsible for a low
level of resistance towards amicoumacin A. As expected, SA-8, like
SA-6, exhibited increased kasugamycin resistance compared to the
wild-type strain (data not shown).
Overexpression of fusA genes with mutant alleles in S.
aureus COL
As described above, the fusA mutations found in two
amicoumacin A-resistant strains locate in domain IV where no
fusidic acid-resistant mutation has previously been isolated. We
also found that the SA-3 and SA-6 fusA mutants are as sensitive to
fusidic acid as the wild-type strain (MIC 0.08 mg/ml). In order to
further characterize antibiotic-resistant phenotypes of fusA muta-
tions, we isolated a fusidic acid-resistant mutant (SA-7) by the
multiple passage method as described in Materials and Methods.
The MIC of SA-7 for fusidic acid was 12.5 mg/ml, which is 156-
fold higher than that of the wild-type strain, whereas SA-7
exhibited the same MIC as the wild-type COL towards
amicoumacin A. Sequence analysis of fusA amplified from the
SA-7 chromosomal DNA identified a point mutation of R464H in
domain III, which is identical to the mutation identified in a fusidic
acid-resistant S. aureus with the small-colony-variant phenotype
[43].
We next checked whether SA-11, the wild-type COL strain
carrying the mutant allele (R464H) of fusA on plasmid pDG148,
confers resistance to fusidic acid. The MIC of this strain for fusidic
acid was around 6.25 mg/ml irrespective of IPTG addition,
probably because the control of the vector IPTG-inducible Pspac
promoter is leaky. In contrast, the MIC of SA-11 for amicoumacin
A was identical to that of the wild-type strain. SA-9 and SA-10 that
express fusA(G530V) and fusA(G531S), respectively, on the multi-
copy plasmid were sensitive to fusidic acid but exhibited 2-fold
higher resistance to amicoumacin A as compared to the wild-type
strain. These results confirmed that the fusA(G530V) and
fusA(G531S) mutations cause amicoumacin A resistance and the
fusA(R464H) mutation causes fusidic acid resistance, but not vice
versa.
Discussion
Amicoumacin A possesses strong bactericidal activity against
MRSA. Xenocoumacin 1, another isocoumarin antibiotic, shares
an identical dihydroisocoumarin moiety with amicoumacin A, but
has a slightly different hydroxy amino acid side chain (Figure 1).
Both compounds exhibit potent activity against gram-positive
bacteria, but only xenocoumacin 1 exhibits activity against
selected gram-negative bacteria, such as some E. coli strains [14].
Conversely, amicoumacin A can kill multi-resistant S. aureus,
whereas xenocoumacin I has no effect on the organism [14]. This
difference in spectra of activity might be due to the difference in
the hydroxy amino acid side chains of the two molecules. In fact, it
has been previously demonstrated that the amide at the terminal
end of the side chain in amicoumacin A is essential for its activity
against MRSA [19].
In this study, we aimed at elucidating the mechanism behind the
strong bactericidal activity of amicoumacin A against MRSA. In
hope of identifying the target of amicoumacin A, we isolated
amicoumacin A resistant strains using the multiple passage
method.
Two different alleles of fusA were found to cause amicoumacin
A resistance, while other alleles lead to fusidic acid resistance as
shown here and in previous work. Fusidic acid binds to an EF-G/
ribosome complex and inhibits EF-G turnover. The crystal
structure of Thermus thermophilus EF-G revealed that domains I
and II are homologous to elongation factor Tu and domains III
and V show structural similarities to ribosomal proteins [45].
Domain IV was shown to protrude from the main body of the
protein. This could explain why no cross-resistance was observed
Table 2. Codon substitution mutations found in amicoumacin-A-resistant COL.
Isolate Fold-resistance Mutated gene (mutation) Function
SA-1 2 SACOL0187 (D343H) RGD-containing lipoprotein
SA-3 8 fusA (G530V) Elongation factor G
oppB (I263F) Oligopeptide permease
dnaG (R190H) DNA primase
SA-6 16 fusA (G531S) Elongation factor G
ksgA (L260Stp) 16 S rRNA methyl transferase
lacD (G86R) tagatose-1,6-bisphosphate aldolase
SACOL0611 (S472P) Glycosyl transferase
doi:10.1371/journal.pone.0034037.t002
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except domain IV and amicoumacin A-resistant mutations in
domain IV. The high resistance to fusidic acid caused by a single
mutation in fusA is attributed to the fact that EF-G is the direct
target of fusidic acid [46]. On the contrary, amicoumacin A
resistance caused by the fusA mutations or the ksgA mutation is only
2-fold. In addition, the resistance increased every 2-fold in parallel
with increased numbers of mutations in such a way that 2-, 8-, and
16-fold increase in MIC was observed in the strains carrying 1, 3,
and 4 point mutations. These results suggest that the direct target
of amicoumacin A is neither EF-G nor proteins encoded by the
other genes, the mutations of which were identified by genome-
wide sequencing.
Table 3. Plasmids and bacterial strains.
Plasmid
pDG148 multi-copy shuttle vector, kanamycin resistance [57]
pMAD integration plasmid with temperature-sensitive replicon [56]
pALG26 pMAD with ksgA(L260stp)
pALG43 pDG148 with fusA(G530V)
pALG44 pDG148 with fusA(G531S)
pALG45 pDG148 with fusA(R464H)
Strain
Bacillus subtilis JH642 Laboratory stock James Hoch
Bacillus pumilus C9 Isolated from the Columbia River Estuary
SAFR032 Kasthuri Venkateswaran
8A1 Bacillus genetic stock center
8A2 Bacillus genetic stock center
8A3 Bacillus genetic stock center
8A4 Bacillus genetic stock center
8E2 Bacillus genetic stock center
8E3 Bacillus genetic stock center
14A1 Bacillus genetic stock center
Bacillus anthracis Sterne 7702 Laboratory stock Terri Koehler
Bacillus cereus ATCC10987 Bacillus genetic stock center
Bacillus thuringiensis NRRL-B4039 Bacillus genetic stock center
Listeria monocytogenes F4244 Laboratory stock
Staphylococcus aureus
RN4220 (MSSA) Laboratory stock Barry Hurlburt
RN6390 (MSSA) Laboratory stock Barry Hurlburt
COL (HA-MRSA) Ambrose Cheung
SA-1 amicoumacin A resistant
SA-3 amicoumacin A resistant
SA-6 amicoumacin A resistant
SA-7 fusidic acid resistant
SA-8 ksgA::pALG26
SA-9 COL with pDG148 carrying fusA(G530V)
SA-10 COL with pDG148 carrying fusA(G531S)
SA-11 COL with pDG148 carrying fusA(R464H)
N315 (HA-MRSA) Ambrose Cheung
Mu50 (HA-MRSA) VISA Ambrose Cheung
USA300 (CA-MRSA) Ambrose Cheung
USA400 (CA-MRSA) Ambrose Cheung
Staphylococcus carnosus/pCX15 Laboratory stock Wolfgang Schumann
Streptococcus pyogenes MGAS5005 Laboratory stock June Scott
Escherichia coli DH5a Laboratory stock
Pseudomonas aeruginosa PA01 Laboratory stock
doi:10.1371/journal.pone.0034037.t003
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by amicoumacin A. The proton ionophore carbomyl cyanide m-
chlorophenylhydrazone (CCCP) was known to induce lrgAB
expression. Since valinomycin, which dissipates Dy, but not
nigericin that depletes DpH across the membrane, has a similar
effect with CCCP on lrg expression, the authors concluded that
lrgAB is upregulated in response to a collapse of Dy [47]. As this
induction of lrgAB transcription requires the LytSR two-compo-
nent signal transduction system, the LytS kinase might respond to
a collapse of Dy [47]. Daptomycin induces genes including lrgAB
that are induced by CCCP, hence it was proposed that a part of
the mechanism of action of daptomycin is membrane depolariza-
tion [48], which is consistent with an earlier study on potassium
release assays [18]. Given transcription of lrgAB is highly induced
by amicoumacin A, it might be possible that membrane
depolarization is at least a part of the mechanism of action.
In this study, we showed that autolysis is highly reduced in cells
grown in the presence of amicoumacin A, which is mainly caused
by decreased activity of murein hydrolase, very likely Atl. A similar
inhibition of autolysis due to reduced murein hydrolase activity
was recently reported in S. aureus treated with Magnolol (5, 59-
diallyl-2, 29-dihydroxybiphenyl) [49]. In this case, transcription of
atl and cidA was reduced and lrgAB transcription was highly
induced after Magnolol treatment. In the case of amicoumacin A,
atl transcription was upregulated and Atl activity was reduced.
There is a precedent for this paradoxical observation. A
teicoplanin-resistant MRSA isolate exhibited an autolysis-deficient
phenotype, although expression of major autolytic genes (atl, lytM,
and lytN) was not changed [50]. As the resistant strain displayed
decreased extracellular murein hydrolase activity, the authors
suggested post-transcriptional regulation of hydrolase activity, the
same conclusion of our study. However, transcription analysis of
cidABC and lrgAB in the teicoplanin-resistant strain ruled out the
possibility of a role for CidA in post-transcriptional control of
murein hydrolase activity. The major murein hydrolase Atl is
involved in peptidoglycan turnover, daughter cell separation after
cell division [51], biofilm formation [52], and penicillin-induced
lysis [53]. Given the roles of Atl in diverse cellular function, its
activity could be tightly controlled through multiple mechanisms.
Future studies are needed to uncover whether amicoumacin A
affects autolysin activity through the LytS-Lrg-Cid pathway.
Materials and Methods
Bacterial strains and media
All of the strains used in this study are listed in Table 3. Bacillus
and Escherichia coli were cultured in 26YT and methicillin-sensitive
S. aureus (MSSA) and MRSA strains were routinely propagated in
tryptic soy broth (TSB) (Cellgro, Manassas, VA). Half-diluted
artificial seawater contains 13.75 g NaCl, 5.3 g MgCl2?6H2O,
1.95 g MgSO4?7H2O, 0.5 g KCl, 0.331 g CaCl2?2H2O, and
0.914 mg FeSO4?7H2O per liter. Antibiotic concentrations used
are; ampicillin, 50 mg/ml; erythromycin, 10 mg/ml; kanamycin,
100 mg/ml (for RN4220) and 20 mg/ml (for COL).
Identification of Bacillus pumilus C9 that produces
amicoumacin A
Water samples were collected from the estuary turbidity
maximum of the North Channel in the Columbia River Estuary
on June 14, 2007 (cruise data link http://www.stccmop.org/
node/510). No specific permissions were required for the
described field studies. The water samples were incubated at
28uC for 8 days and plated on half-diluted artificial seawater
containing 0.5% peptone, 0.1% yeast extract (SPY), and 1.5%
agar. After incubation at 28uC for 3 to 4 days, each bacterium was
purified by isolating a single colony. Isolated bacterium was grown
on SPY agar for 2 to 3 days depending on growth and
antimicrobial activity was determined by overlaying S. aureus
RN6390 in 7 ml brain heart infusion (BHI) (Becton Dickinson,
Franklin Lakes, NJ) with 0.7% soft agar. After incubation at 37uC
overnight, antimicrobial activity was detected as a lysis zone of
RN6390 around a colony of testing bacteria.
Overlay assay to determine anti-microbial spectrum of
amicoumacin A
B. pumilus C9 was streaked onto a small piece (161 cm) of
0.22 mm Millipore filter placed on LB agar plate and incubated at
37uC overnight. The filters were removed and susceptibility to
amicoumacin A was determined by overlaying cultures of testing
strains in 7 ml of BHI or 26YT with soft agar. The plates were
incubated at 37uC for 5 h to overnight.
Isolation of the anti-MRSA substance and purification to
homogeneity
A fresh colony of B. pumilus C9 was used to inoculate LB broth
and was incubated by shaking (150 rpm) at 30uC for 24 h. The
culture supernatant was passed through an AmiconH ultra
filtration membrane (MW 3,000 cutoff, Millipore, Billerica, MA)
and the filtrate was lyophilized. The lyophilized material was
extracted with methanol and the dried methanol extract was
dissolved in 20 mM Tris-HCl (pH 7.0) before applying to a Hi-Q
column to remove impurities. The column was run with 20 mM
Tris-HCl (pH 7.0) at a flow rate of 2 ml/min. The active fractions
were pooled and lyophilized for further purification by reverse
phase high performance liquid chromatography (RP-HPLC). A
C18 semi-preparative column (Vydac 218TP510, 300 A ˚ pore
diameter, 250 mm610 mm, 5 mm particle diameter) was devel-
oped with a gradient of 5% acetonitrile/0.1% trifluoroacetic acid
(TFA) to 50% acetonitrile/0.1% TFA from 5 to 42 min using a
3 ml/min flow rate. The active peak was identified at 29.56 min,
which corresponds to an acetonitrile concentration of 36%. This
fraction was lyophilized prior to analysis by mass spectrometry and
nuclear magnetic resonance (NMR) spectroscopy.
Mass spectrometry analysis
The purified anti-MRSA substance was analyzed by nano-
electrospray ionization (nanoESI) Fourier transform ion cyclotron
resonance (FTICR) mass spectrometry. The Bruker 9.4T Apex-
Qe FTICR (Bruker Daltonics, Billerica, MA) was calibrated
externally using polyethylene glycol. The sample was dissolved in
50% acetonitrile/0.1% formic acid for injection into the nanoESI.
NMR analysis
The purified anti-MRSA substance (200 mg) was dissolved in
300 ml of deuterium oxide (D2O, 99.96% D, Cambridge Isotopes
Laboratories, Cambridge, MA) that also contained 100 mM 2,2-
dimethyl-2-silapentane-5-sulfonate sodium salt (DSS). The sample
was pipetted into a D2O-matched Shigemi NMR tube (Shigemi
Co., Ltd., Tokyo, Japan) for NMR analysis. NMR experiments
were performed on the sample using a Varian Inova 800-MHz
spectrometer equipped with a triple resonance HCN probe and Z-
axis pulsed field gradients.
Partial purification of amicoumacin A
For routine purposes such as MIC and growth inhibitory assay
experiments, partially purified amicoumacin A was used. B. pumilus
C9 culture supernatant was extracted with one-fourth volume of n-
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poured into a separatory funnel and allowed to stand for another
2 h. The organic layer was collected and evaporated at 55uC
overnight. The dried sample was dissolved in 10 mM Tris-HCl
(pH 7.0) and passed through an Amicon ultra filtration membrane
(MW 3,000 cutoff) and the filtrate was re-extracted with butanol.
The dried sample was resuspended with 10 mM Tris-HCl
(pH 7.0) and then passed through LH-20 Sephadex column with
1 ml/min flow rate. The active fractions were pooled and
extracted with butanol. The evaporated sample was dissolved in
10 mM Tris-HCl (pH 7.0) and aliquots were frozen at 280uC
until use.
Growth profile and survival assay of S. aureus COL in the
presence of amicoumacin A
A fresh colony of S. aureus was inoculated and cultured in TSB
overnight at 37uC. Two hundred ml of the overnight culture was
inoculated into a 250 ml flask containing 20 ml of TSB. The flask
was incubated in a 37uC shaker until the OD600 reached 0.4–0.5.
The culture was divided into two flasks, 50 ml of amicoumacin A
or 10 mM Tris-HCl (pH 7.0) was added to each flask and
incubation was continued at 37uC. The readings at OD600 were
recorded at every 1 h. In order to determine the cell survival
profile in response to amicoumacin A, the cells were withdrawn at
0 h and every 1 h after the drug treatment, serially diluted, and
plated onto TSB agar. Numbers of colonies were counted after
overnight incubation at 37uC.
MIC assays
MICs for S. aureus COL were determined by broth microdilu-
tion assays in 96 well microtiter plates. Fifty ml of 2-fold serial
dilutions of amicoumacin A were mixed with an equal volume of
1:100 diluted overnight COL cultures in TSB. Control wells
without drug were also included. The microtiter plate was
incubated at 37uC for 24 h.
Transcriptome analysis
A fresh colony of COL was used to inoculate 2 ml of BHI. The
overnight culture (0.5 ml) was transferred to 50 ml BHI and
incubated at 37uC until OD600<0.5 (t0), when 20 ml of cultures
were withdrawn into 10 ml of ice-cold killing buffer (20 mM
sodium azide, 5 mM MgCl2, 20 mM Tris-HCl, pH 7.5). To the
remaining cultures, amicoumacin A was added at the concentra-
tion leading to around 12% and 20% reduction of OD600 after
10 min and 40 min, respectively. At 10 min and 40 min (t10 and
t40) after the addition of amicoumacin A, 10 to 15 ml of cultures
were harvested by mixing a half volume of ice-cold killing buffer.
Harvested cells were immediately centrifuged at 4uC for 5 min at
7,0006g and washed once with killing buffer before being frozen
at 280uC. Each experiment was performed in biological triplicate.
RNA was prepared from harvested cells using glass beads/phenol
method as previously described [54] and DNA was removed using
RNase-free RQ1 DNase (Promega, Madison, WI). The quality of
RNA was checked by gel electrophoresis and an Agilent
bioanalyzer.
The design and evaluation of the customized StaphChip
oligoarray manufactured by Agilent Technologies (Palo Alto,
CA, USA) used in this study has been described elsewhere [55].
Microarray analysis was employed as described previously [56]. In
short, cDNA was synthesized from 10 mg of total RNA and labeled
by incorporation of Cy5-dCTP or Cy3-dCTP (GE Healthcare,
Little Chalfont, United Kingdom) by direct reverse-transcription
using Superscript II (Invitrogen, Karlsruhe, Germany) and
random hexamers (Promega Madison, WI) as primers. After
denaturation of the RNA primer mix for 10 min at 70uC, cDNA
synthesis was performed in a 50 ml reaction volume at 42uC for
60 min. The concentrations of enzyme and reagents in the reverse
transcription reaction were as follows: Superscript II (400 units),
Cy-dye (1.25 nmol), dATP, dGTP, dTTP (5 nmol each), dCTP
(2.5 nmol), random hexamers (1.25 mg), DTT (0.01 M) and 16
first strand buffer. The Superscript II was heat-inactivated for
10 min at 70uC and template RNA degraded by incubation for
30 min at room temperature with E. coli RNase H (2 units)
(Invitrogen, Karlsruhe, Germany). Labeled cDNA was purified
with the CyScribe GFX Purification Kit following the instructions
of the manufacturer (GE Healthcare, Little Chalfont, United
Kingdom) and Cy-dye incorporation was analysed with a
NanoDrop ND-1000 spectrophotometer (NanoDrop Technolo-
gies, Inc., Rockland, DE). Approximately 500 ng of each labelled
cDNA corresponding to 3–6 pmol of incorporated dye were used
in two-color pool-cDNA (Cy3) versus sample cDNA (Cy5)
competitive hybridization experiments. For the pool-cDNA
synthesis equal amounts of all RNA samples were mixed. The
pool was used as common reference. For each time point (t0,t 10,
and t40), three biologically independent cDNAs were synthesized.
Hybridizations were done in a total sample volume of 40 ml for
17 h at 65uC at 10 rpm in a dedicated hybridization chamber
(Agilent Technologies) and hybridization oven (Robbins Scientific,
Sunnyvale, CA, USA). After hybridization, the slides were washed
for 1 min at room temperature in wash buffer 1 followed by a 1-
min washing step at 37uC with wash buffer 2. The slides were
dried by submersion in acetonitrile for 30 sec. Blocking reagents,
hybridization buffer (Gene Expression Hybridization Kit) and
washing solutions (Gene Expression Wash Buffer Kit) were
purchased from Agilent. Slides were scanned at a 5 mm resolution
(Agilent Technologies Scanner) and fluorescence intensities were
extracted and processed using the Feature Extraction
TM software
version 9.5.3.1 (Agilent Technologies). Local background-sub-
tracted signals of both fluorescence channels were normalized with
the linear LOWESS function. To test whether genes were
differentially expressed in response to amicoumacin A, a Welch’s
t-test (a of ,0.05) with a Bejamini and Hochberg FDR correction
for multiple testing was calculated in Genespring (Agilent
Technologies). Genes that passed the significance test for at least
one time point (t0 versus t10,t 0 versus t40 or t10 versus t40) and with
a mean 2.5-fold up or 2.5-fold down regulation were considered
differentially expressed. Grouping of genes based on expression
profiles was calculated with the hierarchical clustering algorithm
implemented in the multiple experiment viewer MeV [57]. The
complete microarray data set is available at the NIH Gene
Expression Omnibus (GEO) database under record number
GSE31342.
Northern blot analyses
Digoxigenin-labeled RNA probes were prepared by in vitro
transcription with T7 RNA polymerase by using a PCR fragment
(SACOL0678) or plasmid (asp23: pKSAP23 [58]) as template. The
PCR fragment was generated from COL chromosomal DNA
purified with a chromosomal DNA isolation kit (Promega,
Madison, WI) and the respective oligonucleotides (SA0678_-
COL_F: 59-ATGAATAA AGTAGAAGCGAT-39 and SA0678_-
COL_RT7: 59-CTAATACGACTCACTATAGGG AGACTA-
TAATTGTA ATGAAATAT-39). Northern blot analyses were
carried out as previously described [59]. The digoxigenin-labeled
RNA marker I (Roche, Indianapolis, IN) was used to calculate the
sizes of the transcripts. The hybridization signals were detected
using a Lumi-Imager (Roche Diagnostics, Mannheim, Germany)
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Diagnostics, Mannheim, Germany).
Autolysis assay
Cultures at OD600 of around 0.3 were either treated with
amicoumacin A for 45 min or left untreated. Harvested cells from
each culture were washed with cold water and suspended at
OD600 of 1.0 in 50 mM Tris-HCl (pH 7.5) with 0.05% Triton X-
100. Autolysis was measured during incubation at 37uC with
shaking as a decrease in optical density at OD600.
Preparation of purified cell wall
Purified cell wall was prepared as described previously [60]. In
short, cells harvested at OD600 of 0.6 were boiled for 30 min in
4% SDS and washed with water for 4 times. Cells were broken
with glass beads on a Vortex mixer, followed by treatment with a-
amylase (100 mg/ml), DNase (10 mg/ml), RNase (50 mg/ml), and
trypsin (100 mg/ml). The enzymes were inactivated by boiling for
15 min in 1% SDS. Cell wall was collected by centrifugation and
washed twice with water, once with 8 M LiCl, once with 100 mM
EDTA, and twice with water. Acetone-washed pellet was
resuspended in water and lyophilized.
Crude autolytic enzyme extracts
Cells untreated or treated with amicoumacin A for 45 min were
harvested by centrifugation, washed twice with 50 mM Tris-HCl
(pH 7.5). After centrifugation, pellet was suspended in 50 mM
Tris-HCl-2% SDS (at the concentration of 200OD600/ml). After
centrifugation, supernatant was saved as cell-wall-associated
autolysin. As for a source of extracellular autolysins, culture media
were filtered through Millipore filter (0.22 mm) and concentrated
around 40-fold using Amicon Ultra 3 K. The concentrated culture
media were adjusted by standardizing by OD600 harvested cells.
Protein concentration of concentrated media was measured by
BioRad assay and extracellular protein concentrations were at
0.6 mg/ml in thus concentrated cultured media from untreated
and treated cells.
Cell wall hydrolysis in vitro
Purified cell wall isolated from S. aureus COL cultured in the
absence and presence of amicoumacin A was suspended in 50 mM
Tris-HCl (pH 7.5) to an OD600 of 0.7. Cell wall hydrolysis was
initiated by addition of extracellular proteins (90 mg) prepared as
described above. As a control, equal volume of 10 mM Tris-HCl
(pH 7.5) was added. Activities of autolysins were monitored by a
decline in OD600 during incubation at 37uC.
Detection of murein lytic activity was also carried out by
zymographic analysis. Cell-wall-associated proteins prepared from
0.2 OD600 amicoumacin-A-treated or untreated cells (1 mlo f
200OD600/ml cell wall extract) and 1.9 mg of extracellular
proteins were separated in an SDS-10% polyacrylamide gel
containing purified cell wall (1 mg/ml). After electrophoresis, the
gel was rinsed with water and incubated overnight at 37uCi n
25 mM Tris-HCl (pH 8.0) containing 1% Triton X-100. The gel
was rinsed with water and stained with 0.1% methylene blue in
0.01% KOH.
Isolation of mutants with decreased susceptibility to
amicoumacin A and fusidic acid
Mutants were isolated by multiple passage methods through
progressively increasing concentration of amicoumacin A or
fusidic acid. Bacterial cultures that grew at the highest concentra-
tions of the drug were used as an inoculum for the subsequent
culture. Three amicoumacin A-resistant strains (SA-1, SA-3, and
SA-6) and one fusidic acid-resistant strain (SA-7) were used for
further studies.
Genotypic characterization of amicoumacin A-resistant
mutants
Comparative genome sequencing (CGS) was used to identify
chromosomal mutations in amicoumacin A-resistant mutants of S.
aureus COL, SA-1 (2-fold increase in MIC), SA-3 (8-fold), and SA-6
(16-fold). Genomic DNA was purified from the wild-type and
mutant strains using WizardH Genomic DNA Purification Kit
(Promega, Madison, WI). DNA was sheared to the fragments of less
than 800 bp using Nebulizer kit (Invitrogen, Carlsbad, CA). The
fragments were blunt-ended using end-it DNA repair kit (Epicentre,
Madison, WI) and ‘‘A-tailing’’ of the fragments was done using
Klenowexo-minusanddATP.Theadapterswithdifferentbarcodes
and an overhang-T were ligated to the A-tailed fragments using fast
link kit (Epicentre, Madison, WI). The ligated products were loaded
onto 2% agarose gels. A 400–450 bp range of DNA was cut from
the gel to exclude the unligated adapters and eluted using gel
extraction kit (Qiagen, Valencia, CA). PCR was carried out using
primers DL139 (59-AATGATACGGCGACCACCGAGATCTA-
CACTCTTTCCCTACACGA-39) and DL140 (59-CAAGCA-
GAAGACGGCATACGAGATCGGTCTCGGCATTCCTGC-
TGA AC-39) and PfuUltra
TM II Fusion HS DNA polymerase
(Stratagene, Santa Clara). The PCR fragments were cloned using
TOPO blunt kit (Invitrogen, Carlsbad, CA) and 10 randomly
chosenclonesfrom each librarywere sequenced to check the quality
of genomic DNA library. The library DNA was diluted to 20 nM
andsent totheGenomicsCore FacilityatTuftsUniversitySchool of
Medicine for single-end sequencing in Illumina HiSeq 2000. The
analysis was carried out using the wild-type COL genome as a
controland later comparingwith S. aureusCOL genomeavailable at
NCBI (Accession no. NC_002951).
Construction of ksgA mutants
The ksgA gene carrying the mutation (L260stop) was amplified
using primers, ksgAFEcoRI (59-GCTCGAATTCGGATAATAAA-
GATA TTGCAACACC-39, EcoRI site is underlined) and ksgAR-
BamHI (59-GATCGGATCCGCCTCCATTGGCTTTCAG TA-
CAATAC-39, BamHI site is underlined), and chromosomal DNA
isolated from the SA-6 strain as a template. The PCR product
digested with EcoRI and BamHI was cloned into pMAD vector [61]
digested with the same enzymes to generate pALG26. pALG26 was
introduced into RN4220 by electroporation with selection for
erythromycin resistance (Erm
r)a t3 0 uC. Bacteriophage w11-mediat-
ed transduction was used to introduce pALG26 from the RN4220
transformant into COL by selecting transductants on TSB agar plates
containing erythromycin and X-gal at 30uC. A single clone of the
transductantswasgrown inTSBcontainingerythromycinat 30uCf or
3–4 h and at 42uC for 6 h before plating on TSB agar plates
containing erythromycin and X-gal. After incubation at 42uC, light
blue colonies were obtained, which resulted from a single crossover
recombination between the plasmid-born and the chromosomal ksgA
genes. The recombinant strain, SA-8, was checked for resistance
against kasugamycin and amicoumacin A.
Overexpression of fusA carrying the mutant alleles in S.
aureus COL
The wild-type and the fusA mutant (G530V, G531S, R464H)
genes were amplified using primers fusASalIF (59-GATCGTC-
GACATGGCTAGAGAATTTTCA-39, SalI site is underlined)
and fusASphIR (59-GATCGCATGCTTATTCACCTTTATT-
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isolated from SA-3, SA-6, and SA-7, respectively. Each PCR
product was digested with SalI and SphI, and ligated with pDG148
[62] digested with the same enzymes to generate pALG43 (for
G530V), pALG44 (for G531S), and pALG45 (for R464H). These
plasmids were first transformed into RN4220, then introduced
into COL by w11-mediated transduction as described above. The
resultant COL strains, SA-9 (G530V), SA-10 (G531S), and SA-11
(R464H), were examined for fusidic acid- and amicoumacin A-
susceptibility by microdilution method.
Supporting Information
Table S1 Changes in global transcription of S. aureus
COL in response to amicoumacin A. Hierarchical clustering
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